Shares of Dechra Pharmaceuticals plc (LON:DPH) have received a consensus rating of “Buy” from the eight research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is GBX 1,733.50 ($22.87).

Several equities analysts have recently issued reports on the company. Stifel Nicolaus reissued a “hold” rating and set a GBX 1,550 ($20.45) target price on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, July 11th. Investec reissued a “buy” rating and set a GBX 1,840 ($24.27) target price on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. N+1 Singer reissued a “buy” rating and set a GBX 1,666 ($21.98) target price on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Numis Securities Ltd reissued an “add” rating and set a GBX 1,890 ($24.93) target price on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Finally, Panmure Gordon reissued an “under review” rating on shares of Dechra Pharmaceuticals plc in a research note on Thursday, April 20th.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/04/dechra-pharmaceuticals-plc-dph-given-average-rating-of-buy-by-analysts.html.

In related news, insider Ian Page sold 134,500 shares of the company’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of GBX 1,927 ($25.42), for a total value of £2,591,815 ($3,418,829.97).

Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 1.08% during mid-day trading on Friday, hitting GBX 1780.00. 49,430 shares of the stock traded hands. Dechra Pharmaceuticals plc has a 52 week low of GBX 1,189.00 and a 52 week high of GBX 1,970.00. The stock’s market cap is GBX 1.65 billion. The firm’s 50-day moving average is GBX 1,746.80 and its 200-day moving average is GBX 1,686.03.

Dechra Pharmaceuticals plc Company Profile

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals plc (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.